Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
How Do Erythroid Maturation Agents Treat Beta Thalassemia?
EMAs are a newer treatment option to improve symptoms and quality of life for people with beta thalassemia.
Written by Lauren Smith, MA | Reviewed by Karen Hovav, MD, FAAP
Updated on May 15, 2025Erythroid maturation agents, or EMAs, are a newer treatment option for beta thalassemia. In this video, learn how EMAs work to improve anemia and reduce the risk of complications from beta thalassemia, according to Jonathan Feld, MD, Hematology Specialist at The Mount Sinai Hospital in New York City.
Additional Medical Contributors
- Jonathan Feld, MDJonathan Feld, MD, is a hematology specialist at The Mount Sinai Hospital.
References
Bajwa, H., et al. (2022). Thalassemia. StatPearls.
Bristol Myers Squibb. (2022). REBLOZYL [package insert].
View All References (3)
Cappellini, M. D., et al. (2021). The use of luspatercept for thalassemia in adults. Blood Advances.
Centers for Disease Control and Prevention. (2023). Thalassemia: Complications and treatment.
Rasel, M., et al. (2022). Transfusion iron overload. StatPearls.
GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.